Zim Laboratories Ltd Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 2
Fundraise
No
Order
N/A
Capex
Yes
1 of 4 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3See what Zim Laboratories Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
NoSee what Zim Laboratories Ltd management said on order book — free account, 30 seconds.
Capex plans
YesTrack Zim Laboratories Ltd — get its next earnings analysis in your feed
Margin guidance
Category 2Order book
How does Zim Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Zim Laboratories Ltd rank in Pharmaceuticals & Biotechnology?
Compare Zim Laboratories Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Zim Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…